Company registration number 07608815 (England and Wales)
KINGSHIELD PHARMACY LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2025
PAGES FOR FILING WITH REGISTRAR
KINGSHIELD PHARMACY LIMITED
COMPANY INFORMATION
Director
B Patel
Company number
07608815
Registered office
6 Ritherdon Road
London
SW17 8QD
Accountants
Y R Associates
6 Ritherdon Road
London
SW17 8QD
KINGSHIELD PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
KINGSHIELD PHARMACY LIMITED
BALANCE SHEET
AS AT
31 JULY 2025
31 July 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
580,935
611,918
Tangible assets
4
4,922
6,563
585,857
618,481
Current assets
Stocks
5
91,587
102,337
Debtors
6
65,737
51,654
Cash at bank and in hand
4,607
18,515
161,931
172,506
Creditors: amounts falling due within one year
7
(104,180)
(98,053)
Net current assets
57,751
74,453
Total assets less current liabilities
643,608
692,934
Creditors: amounts falling due after more than one year
8
(357,325)
(399,875)
Provisions for liabilities
(973)
(1,326)
Net assets
285,310
291,733
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
285,210
291,633
Total equity
285,310
291,733
KINGSHIELD PHARMACY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 JULY 2025
31 July 2025
- 2 -

For the financial year ended 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 22 April 2026
B Patel
Director
Company registration number 07608815 (England and Wales)
KINGSHIELD PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2025
- 3 -
1
Accounting policies
Company information

Kingshield Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is 6 Ritherdon Road, London, England, SW17 8QD.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements have been prepared under the historical cost convention.

1.2
Revenue

Turnover is measured at fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

1.3
Intangible fixed assets - goodwill

Goodwill, being the amount paid in connection with the acquisition of a business in 2014, is being amortised evenly over its estimated useful life of thirty years.

 

1.4
Tangible fixed assets

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% on reducing balance
1.5
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

1.6
Taxation
Current tax

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.


Current or deferred taxation assets and liabilities are not discounted.


Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

 

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.


Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.


Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

 

KINGSHIELD PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
1
Accounting policies
(Continued)
- 4 -
1.7
Retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

 

1.8
Leases

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

 

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
8
8
3
Intangible fixed assets
Goodwill
£
Cost
At 1 August 2024 and 31 July 2025
929,500
Amortisation and impairment
At 1 August 2024
317,582
Amortisation charged for the year
30,983
At 31 July 2025
348,565
Carrying amount
At 31 July 2025
580,935
At 31 July 2024
611,918
KINGSHIELD PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
- 5 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 August 2024 and 31 July 2025
62,585
Depreciation and impairment
At 1 August 2024
56,022
Depreciation charged in the year
1,641
At 31 July 2025
57,663
Carrying amount
At 31 July 2025
4,922
At 31 July 2024
6,563
5
Stocks
2025
2024
£
£
Stocks
91,587
102,337
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
42,257
48,325
Other debtors
7,001
1,950
49,258
50,275
2025
2024
Amounts falling due after more than one year:
£
£
Amounts owed by group undertakings
16,479
1,379
Total debtors
65,737
51,654
KINGSHIELD PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
- 6 -
7
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans and overdrafts
9,703
-
0
Trade creditors
57,929
63,957
Corporation tax
16,778
9,039
Other taxation and social security
5,749
14,162
Other creditors
14,021
10,895
104,180
98,053
8
Creditors: amounts falling due after more than one year
2025
2024
£
£
Amounts owed to group undertakings
357,325
399,875
9
Related party transactions

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

2025-07-312024-08-01falsefalsefalse22 April 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityB Patel076088152024-08-012025-07-3107608815bus:Director12024-08-012025-07-3107608815bus:RegisteredOffice2024-08-012025-07-31076088152025-07-31076088152024-07-3107608815core:NetGoodwill2025-07-3107608815core:NetGoodwill2024-07-3107608815core:OtherPropertyPlantEquipment2025-07-3107608815core:OtherPropertyPlantEquipment2024-07-3107608815core:CurrentInventories2025-07-3107608815core:CurrentInventories2024-07-3107608815core:CurrentFinancialInstrumentscore:WithinOneYear2025-07-3107608815core:CurrentFinancialInstrumentscore:WithinOneYear2024-07-3107608815core:Non-currentFinancialInstrumentscore:AfterOneYear2025-07-3107608815core:Non-currentFinancialInstrumentscore:AfterOneYear2024-07-3107608815core:CurrentFinancialInstruments2025-07-3107608815core:CurrentFinancialInstruments2024-07-3107608815core:ShareCapital2025-07-3107608815core:ShareCapital2024-07-3107608815core:RetainedEarningsAccumulatedLosses2025-07-3107608815core:RetainedEarningsAccumulatedLosses2024-07-3107608815core:Goodwill2024-08-012025-07-3107608815core:FurnitureFittings2024-08-012025-07-31076088152023-08-012024-07-3107608815core:NetGoodwill2024-07-3107608815core:NetGoodwill2024-08-012025-07-3107608815core:OtherPropertyPlantEquipment2024-07-3107608815core:OtherPropertyPlantEquipment2024-08-012025-07-3107608815core:Non-currentFinancialInstruments2025-07-3107608815core:Non-currentFinancialInstruments2024-07-3107608815bus:PrivateLimitedCompanyLtd2024-08-012025-07-3107608815bus:FRS1022024-08-012025-07-3107608815bus:AuditExemptWithAccountantsReport2024-08-012025-07-3107608815bus:SmallCompaniesRegimeForAccounts2024-08-012025-07-3107608815bus:FullAccounts2024-08-012025-07-31xbrli:purexbrli:sharesiso4217:GBP